A Link Between Allergy and Hematological Malignancies? Focus on Possible Mechanisms and the Potential Role of Biological Therapies.

Immune dysregulation has been widely recognized in the international literature as an underlying condition for hematological malignancies and allergic disorders. This commonality has led researchers to study the potential association, positive or negative, between blood cancers and allergy, but the results remain unclear. The cellular and molecular mechanisms underlying allergic inflammation appear to have dual effects on immune surveillance, potentially positively or negatively influencing carcinogenesis in solid tumors. The same mechanisms may also play a role in the genesis of hematological malignancies, but there is little evidence in the literature to support this. In our review, we explored the possible link between the immune pathways involved in allergic responses and the mechanisms underlying hematological malignancies, focusing on Th2 responses, the activity of inflammatory cells, cytokines, and the emerging role of alarmins. Furthermore, our review aims to assess the association between biologics and the risk of neoplastic disease, with a focus on hematological malignancies. A deeper understanding of shared immune dysregulation pathways and the interactions between various cell types could lead to new preventive or therapeutic approaches for patients with hematological malignancies. Understanding the complex roles of various cellular and molecular mediators of Th2 inflammation in stimulating or inhibiting tumor growth could be a key goal of future research, paving the way for innovative targeted therapies, especially at a time when immunotherapy and monoclonal antibody therapies are increasingly important and effective.